Anti-HER2 vaccines: new prospects for breast cancer therapy - Wikidata - awgldk - TriplyDB

Anti-HER2 vaccines: new prospects for breast cancer therapy

Anti-HER2 vaccines: new prospects for breast cancer therapy

http://www.wikidata.org/entity/Q34105959

about

HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3 Antitumor activity of SA12, a novel peptide, on SKBr-3 breast cancer cells via the mitochondrial apoptosis pathway Current neoadjuvant treatment options for HER2-positive breast cancer.Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects.The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro.Adaptive Immune Responses and HER2/neu Positive Breast Cancer.Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.Clinical applications of mouse models for breast cancer engaging HER2/neu.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy Potential targets for pancreatic cancer immunotherapeutics.Immunotherapy of cancer: reprogramming tumor-immune crosstalk.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Immunotherapy for breast cancer: past, present, and future.Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells.Targeting soluble proteins to exosomes using a ubiquitin tag.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.Modern strategies and capabilities for activation of the immune response against tumor cells.Studies on the secondary metabolites of a Pseudoalteromonas sp. isolated from sediments collected at the northeastern coast of Brazil.Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform.Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.Breast Cancer Vaccines: New Insights.Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.Selection, purification and characterization of a HER2-targeting soluble designed ankyrin repeat protein by E.coli surface display using HER2-positive melanoma cells.Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.Construction and characterization of a new chimeric antibody against HER2.Virus-like particle display of HER2 induces potent anti-cancer responses.

P2860

Q26822730-6D265970-FC89-4083-BE09-2CE2507548EF Q33577507-BAAED948-290A-4C55-ADA4-DB1830294190 Q34120400-AB881B82-F7A6-45F6-8DB1-3ADEFAD4B636 Q34659512-F9B25183-EA46-4D04-94F3-7ED757470AA3 Q35161655-8BA12938-5912-4B31-BC95-0580DD67A4AD Q35164938-C098D02D-2C9A-45C5-BD35-FAB402158D5C Q35225664-054659FA-C79E-4235-AB93-63FD1373D52C Q35556207-C9538780-A4B1-43F8-8D35-E86E53996C8E Q35763466-A0B366C9-627A-46C9-93A9-06107921F7B6 Q36032635-08F5A032-E0EA-4698-9C00-D603C093C85F Q36563145-270C66FD-67E2-41C1-94FC-3658E49F384E Q36607857-B7006587-2428-4461-BA08-B26C045D3FAD Q36777133-7825FB6F-5DFF-461F-9543-AA1E84C4EEB9 Q37076922-6E6668A4-89CA-4785-909F-0C8909C6D649 Q37078963-A67CF63E-019B-4D85-857D-76845F6E7CD7 Q37205811-A992B37B-FF39-4E2A-B14C-DAC9D2246B47 Q37607675-AAA3CCE9-E452-467A-B9AE-37400686B921 Q37691212-511853E7-A540-442F-B7E6-C2404B208B3B Q37706331-5B113B20-15C9-4FCF-9FC4-DE550213F0F3 Q37861220-45FB3586-326C-4E9C-A7D3-F2A0A2C11EEC Q38055479-E904D6CD-AE43-4038-81AA-E661DE32E286 Q38076053-2175BB70-D0D0-410D-8F8E-517AF0921E5C Q38098973-B5AD611F-1C05-4E00-8719-FCB165791077 Q38215394-E5E5DAD1-3AEA-47E6-B8D4-2CBC9ADDE3DC Q38787696-4BF3990D-DAA3-4B37-88B9-50FAAEB7DE2B Q38791070-8CC7CE0C-CCFB-4511-9047-7549013F9AA7 Q38819123-DFBFC967-575A-4DFA-8E0F-AF08245ABBEA Q38867798-5E796052-A135-4696-873B-6E36B49CE092 Q39042958-9D61A286-9741-40C4-A2F8-6C92F864793B Q39312666-A6C4D88A-183B-46DD-B99B-E4E92E258E6B Q39394577-749FD33C-E04D-4601-BDF7-F0F7E791152C Q40674386-EFA50E6C-CF1E-4C1D-8A6C-451DC88CFE8A Q41787921-3F8EA86F-7D7C-4BAA-86BC-21E81F97F9C7 Q41936513-18CF0D22-8CFF-44A3-B21D-451D54A0E71F Q42683276-46845B56-2520-4A6E-918F-EC3D36831168 Q46757140-21C5037C-87F8-4F07-8CBB-149E9A27B16A Q47219728-A17DD36C-7541-4CE2-9B97-276B96C5F57D Q49567029-A35C4145-91A2-40BD-A109-C97AB1ED0051 Q50856283-5C34FD56-3D7E-4B3F-A4EC-0C0B3BF96E13 Q52699878-8648141F-A734-4AD2-9380-F69BADF4AE00

P2860

Anti-HER2 vaccines: new prospects for breast cancer therapy

http://www.wikidata.org/entity/Q34105959

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-HER2 vaccines: new prospects for breast cancer therapy

@ast

Anti-HER2 vaccines: new prospects for breast cancer therapy

@en

Anti-HER2 vaccines: new prospects for breast cancer therapy

@nl

type

label

Anti-HER2 vaccines: new prospects for breast cancer therapy

@ast

Anti-HER2 vaccines: new prospects for breast cancer therapy

@en

Anti-HER2 vaccines: new prospects for breast cancer therapy

@nl

prefLabel

Anti-HER2 vaccines: new prospects for breast cancer therapy

@ast

Anti-HER2 vaccines: new prospects for breast cancer therapy

@en

Anti-HER2 vaccines: new prospects for breast cancer therapy

@nl

P1433

Q34105959-AE921F26-FFD6-4C0F-A5D1-A14E6007E34E

P1476

Q34105959-FF5ECDAF-4AA3-4C1E-9072-1C81FC0F6C38

P2093

Q34105959-126BEA93-7D2B-4F26-A7F2-CEA02274812A

Q34105959-3C637DE6-24E9-4DAC-91B8-F3DA6C747B38

Q34105959-99C16F85-4D32-44D8-A11B-F43A5332E381

Q34105959-E6ED0CE8-DC7D-4B66-836A-8B8C1EFFD13C

P2860

Q34105959-000A43B5-5203-460F-9D70-9382FE6A0776

Q34105959-06A01993-5C51-4672-A317-BEC8BB6EAF48

Q34105959-07DB8BE9-0CDD-441C-9600-77EF104F12F6

Q34105959-07FCD40D-5845-408A-B1C7-0E8B3BC72020

Q34105959-0AD9D1C2-92A1-4A16-A9FF-F8CA4FE97731

Q34105959-0C887279-2730-42F1-A618-8976B663BFA8

Q34105959-101D3577-4288-4DB3-9995-6CD20CBD87D9

Q34105959-13121372-EA3A-47CC-9DFD-B12ABE2390B5

Q34105959-15822ACA-7CF4-49A5-BBF4-AB0686384320

Q34105959-17D86931-0D80-46C6-AC8D-B294E1EF8308

P2888

Q34105959-09EA4713-2DBF-46CE-A27F-339831D4F423

P304

Q34105959-272B946E-309F-45B4-BE5C-AA964CB758DD

P31

Q34105959-2BE69BF1-31A3-4F41-B49E-534E7C5F533D

P356

Q34105959-22BAF1C4-5204-4BC2-B7BA-CC03ACDAD7CD

P433

Q34105959-76A9C3D5-3258-4B7F-A45F-2F04DD0A5C76

P478

Q34105959-1A10CB7B-DEA7-4ED0-8B62-339D50252488

P50

Q34105959-68983A92-877C-494B-9FD0-8E41C7600505

P577

Q34105959-539BC2F6-8817-4ADE-8506-AD8C86745336

P5875

Q34105959-CA15D912-2D0F-4D1E-B0AA-2B4EDE6C0B5D

P6179

Q34105959-CC26D3A4-5EBB-4405-9E6A-F44804C3EA6A

P698

Q34105959-9B79643A-844B-4C31-B250-EFDEBD1FDB8B

P932

Q34105959-D9702230-C318-4363-87FD-A9E098055168

P356

S00262-010-0869-2

P1433

Cancer Immunology, Immunotherapy

P1476

Anti-HER2 vaccines: new prospects for breast cancer therapy

@en

P2093

André Pèlegrin

http://www.w3.org/2001/XMLSchema#string

Isabelle Navarro-Teulon

http://www.w3.org/2001/XMLSchema#string

Maha Zohra Ladjemi

http://www.w3.org/2001/XMLSchema#string

William Jacot

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

Cancer immunoprevention

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

The chemokine system in diverse forms of macrophage activation and polarization

Breast cancer vaccines: a clinical reality or fairy tale?

Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.

P2888

s00262-010-0869-2

P304

1295-1312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0869-2

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Chardès

P577

2010-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44658171

http://www.w3.org/2001/XMLSchema#string

P6179

1024628302

http://www.w3.org/2001/XMLSchema#string

P698

20532501

http://www.w3.org/2001/XMLSchema#string

P932

2933838

http://www.w3.org/2001/XMLSchema#string